Evaxion Biotech (EVAX) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500, Nasdaq futures edge up as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil rises as US-Iran conflict clouds peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update
May 13, 2021 7:30 AM EDTRaised net proceeds of $27.9 million in U.S. initial public offering in February 2021Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2Product candidates EVX-03 and EVX-B1 progressing through pre-clinical developmentCash reserves of $27 million at March 31, 2021
COPENHAGEN, Denmark, May 13, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion or the Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the first quarter 2021 financial results and... More
